Additional Phase 1 data suggest MPL may inhibit motor neurone disease (final) Category: News and Announcements 2023By PharmAust22/08/2023Related postsChief Executive Officer Appointment28/08/2023Cohort 3 Pharmacokinetics in MND Patients Completed09/08/2023Appendix 4C and Quarterly Update31/07/2023MND Trial Successfully Completes 3rd Patient Cohort28/07/2023Canine Trial Update13/07/2023Results show MPL suppresses biomarkers associated with MND11/07/2023